Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 16/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 5/20 | 0.44 |
| ▸ | GCGR | P47871 | 2/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.42 |
| ▸ | RAF1 | P04049 | 3/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 3/20 | 0.42 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5851456 | 0.82 | MAPK14 (0.57) | MAPK14MAPK11GCGRMAPK13RAF1 | |
| SCHEMBL5850448 | 0.82 | MAPK14 (0.44) | MAPK14MAPK11GCGRMAPK13MAPK12 | |
| SCHEMBL5851703 | 0.80 | MAPK14 (0.44) | MAPK14MAPK11GCGRMAPK13RAF1 | |
| SCHEMBL5850015 | 0.79 | MAPK14 (0.60) | MAPK14MAPK11 | |
| SCHEMBL5852002 | 0.79 | — | — | |
| SCHEMBL5850017 | 0.77 | MAPK14 (0.54) | MAPK14MAPK11GCGRMAPK13RAF1 | |
| SCHEMBL5849840 | 0.77 | MAPK14 (0.44) | MAPK14MAPK11GCGRMAPK13RAF1 | |
| SCHEMBL5851748 | 0.76 | MAPK14 (0.46) | MAPK14MAPK11 | |
| SCHEMBL5850174 | 0.75 | MAPK14 (0.42) | MAPK14MAPK11GCGR | |
| SCHEMBL22589403 | 0.74 | MAPK14 (0.72) | MAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122666-B2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-10-17 | — | — | US | disclosed |
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2006-06-15 | — | — | US | disclosed |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2005-12-22 | — | — | US | disclosed |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | SANKYO COMPANY, LIMITED (JP) | 2004-03-18 | — | — | US | disclosed |
| EP-1352906-A1 | COMPOSITIONS FOR PREVENTION OR TREATMENT OF HEPATOPATHY | Sankyo Company, Limited (JP) | 2003-10-15 | — | — | EP | disclosed |
| EP-1070711-A2 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128756-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1A, IL1B | MAPK14 3902/4885MAPK11 3630/4885GCGR 3466/4885 |
| US-20050283006-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, CNKSR1, IL1A | MAPK14 4157/4885MAPK11 3723/4885GCGR 2716/4885 |
| US-20040054173-A1 | Heteroaryl-substituted pyrrole derivatives, their preparation and their therapeutic uses | IL2, IL1B, IL1A | MAPK14 3593/4885MAPK11 3364/4885GCGR 2810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.